SciSparc Ltd., a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced it has been granted an approval from the Israeli Medical Cannabis Agency (IMCA) at the Israeli Ministry of Health to conduct its clinical trial for SCI-210 in children suffering from autism spectrum disorder (ASD). SCI-210 is a proprietary combination of cannabidiol (CBD) and CannAmide.
With this approval, the company has secured all necessary approvals to commence the clinical trial in Israel, including approvals from the Soroka University Medical Center Ethics Committee and Israeli Ministry of Health.
The company's goal is to sell SCI-210 first in Israel and then in various regions of the world subject to obtaining appropriate regulatory approvals.
"The initiation of this clinical trial represents a significant step forward for our proprietary SCI-210 as we work to develop a novel treatment for children and adolescents with ASD. Given there are very few safe and effective treatments for reducing ASD symptoms, we believe that SCI-210 potentially introduces a safe and effective solution to this condition, which represents a clear unmet medical need,
